TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28716003

Group type: EXPERIMENTAL
Intervention: RENEW (eccentric resistance exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRAD (traditional resistance exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RENEW
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRAD
Number of subjects: 0
Study: 26277295

Group type: EXPERIMENTAL
Intervention: 5 mg of intracoronary diltiazem
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 24151589

Group type: EXPERIMENTAL
Intervention: NMES + Ex (neuromuscular electrical stimulation combined with exercises)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ex (exercise program)
Number of subjects: 100
Study: 20369218

Group type: EXPERIMENTAL
Intervention: Yoga intervention (Dru Yoga, 60-minute class once a week for six weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention)
Number of subjects: 48
Study: 18774746

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1214
Study: 16840514

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenous infusion at 125 mg kg(‐1) h(‐1) for 15 min, then 25 mg kg(‐1) h(‐1) for 20 min prior to and throughout exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (CON)
Number of subjects: 8
Study: 12790813

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 30
Study: 10959784

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth disinfection with chlorhexidine (Fdis)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth root planing without chlorhexidine (FRp)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (standard treatment with quadrant root planing)
Number of subjects: 36
Study: 8638837

Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg/h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ropivacaine (total and unbound plasma concentrations)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ropivacaine (unbound clearance)
Number of subjects: 20
Study: 1350610

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg four times a day)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (500 mg four times a day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sulfasalazine (2 gm daily) alone
Number of subjects: 132
Study: 6087397

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 31402562

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev) in combination with sequential chemotherapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev)
Number of subjects: 132
Study: 28971905

Group type: EXPERIMENTAL
Intervention: 6‐methylprednisolone 1 mg/kg/day
Number of subjects: 171

Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 171
Study: 26499860

Group type: EXPERIMENTAL
Intervention: Health-based intervention program
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Islamic-based intervention program
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Combined intervention group (Health + Islamic)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 427
Study: 23640303

Group type: EXPERIMENTAL
Intervention: Group map-based program (intervention)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Group education on cholesterol and blood pressure (control)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 134
Study: 21247455

Group type: EXPERIMENTAL
Intervention: Mental health workers trained in a cultural module
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mental health workers not trained in a cultural module
Number of subjects: 150
Study: 19056744

Group type: EXPERIMENTAL
Intervention: High-impedance leads
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard impedance leads
Number of subjects: 40
Study: 16567671

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 81
Study: 12796664

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises (PFE) with biofeedback and physical therapist guidance, performed before and after surgery, with home exercises twice daily after surgery.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no formal PFE instructions), underwent surgery only.
Number of subjects: 38
Study: 10843163

Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 9
Study: 8666626

Group type: EXPERIMENTAL
Intervention: Cemented prosthesis
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-cemented prosthesis
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Venography (in patients with isolated distal thrombi)
Number of subjects: 250
Study: 1450186

Group type: EXPERIMENTAL
Intervention: Remoxipride (30 to 90 mg)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Remoxipride (120 to 240 mg)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Remoxipride (300 to 600 mg)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Haloperidol (15 to 45 mg)
Number of subjects: 242
Study: 6428380

Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous biliary drainage (PBD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous transhepatic cholangiography (PTHC) followed immediately by operation (Control)
Number of subjects: 50
Study: 29260507

Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with bortezomib and dexamethasone (DVd)
Number of subjects: 8
Study: 27097939

Group type: EXPERIMENTAL
Intervention: Otoacoustic emissions (OAE) measurements before surgery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Otoacoustic emissions (OAE) measurements during surgery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Otoacoustic emissions (OAE) measurements after surgery
Number of subjects: 39
Study: 25204191

Group type: EXPERIMENTAL
Intervention: Anxin granules combined with tirofiban
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tirofiban alone
Number of subjects: 120
Study: 22878383

Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin hydrochloride
Number of subjects: 513

Group type: COMPARATOR
Intervention: 5% povidone‐iodine
Number of subjects: 513

Group type: COMPARATOR
Intervention: 0.4% amikacin sulphate
Number of subjects: 513
Study: 20976066

Group type: EXPERIMENTAL
Intervention: FTO rs9939609 A allele
Number of subjects: 1550
Study: 17822751

Group type: EXPERIMENTAL
Intervention: HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off in age group 35-60
Number of subjects: 45307

Group type: EXPERIMENTAL
Intervention: HPV testing alone as screening test in age group 25-34
Number of subjects: 45307

Group type: EXPERIMENTAL
Intervention: Adding liquid-based cytology as screening test in age group 35-60
Number of subjects: 45307

Group type: EXPERIMENTAL
Intervention: HPV positive women triaged by cytology in age group 25-34
Number of subjects: 45307
Study: 16201396

Group type: EXPERIMENTAL
Intervention: Computer-based video support system (Visual Training System) during practical training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group received instruction in scaling and root planing instruments during a 7-hour seminar and 2 hours of manual practice
Number of subjects: 84
Study: 12009297

Group type: EXPERIMENTAL
Intervention: Polysaccharide Nm vaccine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 157
Study: 10427132

Group type: EXPERIMENTAL
Intervention: Urinary telomerase activity before TUR
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Urinary telomerase activity after TUR
Number of subjects: 26
Study: 7481633

Group type: EXPERIMENTAL
Intervention: CAGE test
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control group (no CAGE test)
Number of subjects: 416
Study: 2287557

Group type: EXPERIMENTAL
Intervention: Combination treatment of pentoxifylline and theophylline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Theophylline administration alone
Number of subjects: 9
Study: 6992196

Group type: EXPERIMENTAL
Intervention: Metrizamide (nonionic contrast medium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylglucamine iothalamate (ionic contrast medium)
Number of subjects: 0
Study: 31825075

Group type: EXPERIMENTAL
Intervention: High-carbohydrate beverage (CHO; 210 kcal; 0 g fat/56 g carbohydrates/0 g protein)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-carbohydrate beverage (CHO)
Number of subjects: 17
Study: 31229045

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-concentration tacrolimus and steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolate, tacrolimus, and steroids
Number of subjects: 0
Study: 26035033

Group type: EXPERIMENTAL
Intervention: Febuxostat plus diacerein
Number of subjects: 64

Group type: COMPARATOR
Intervention: Febuxostat alone
Number of subjects: 64
Study: 25885664

Group type: EXPERIMENTAL
Intervention: PrEP (Pre-exposure prophylaxis)
Number of subjects: 99009

Group type: EXPERIMENTAL
Intervention: Rapid HIV tests
Number of subjects: 99009

Group type: EXPERIMENTAL
Intervention: Total visits with positive rapid test results
Number of subjects: 99009
Study: 23688534

Group type: EXPERIMENTAL
Intervention: Luteolin and quercetin dietary supplement (100 mg luteolin, 70 mg quercetin, 30 mg rutin per capsule, 1 capsule per 10 kg weight per day with food)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Luteolin and quercetin dietary supplement
Number of subjects: 50
Study: 21268724

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus adefovir dipivoxil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adefovir dipivoxil alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus adefovir dipivoxil or peginterferon alfa‐2a alone
Number of subjects: 90
Study: 19265788

Group type: EXPERIMENTAL
Intervention: High sodium (HS) intake (200 mEq/24 h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low sodium (LS) intake (10 mEq/24 h)
Number of subjects: 80
Study: 17393191

Group type: EXPERIMENTAL
Intervention: 650 nm laser
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 780 nm laser
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 12496059

Group type: EXPERIMENTAL
Intervention: Nicotine gum (part of nicotine replacement therapy)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Urine concentrations of anabasine and anatabine
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 304
Study: 10527226

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vecuronium 0.15 mg/kg
Number of subjects: 32
Study: 7726306

Group type: EXPERIMENTAL
Intervention: Imipramine (low dose: 0.5 mg/kg per day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Imipramine (medium dose: 1.5 mg/kg per day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Imipramine (high dose: 3.0 mg/kg per day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Imipramine (all doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Imipramine (high dose)
Number of subjects: 80
Study: 2019075

Group type: EXPERIMENTAL
Intervention: Skin perfusion pressure using an isotope technique
Number of subjects: 226

Group type: COMPARATOR
Intervention: Doppler ankle pressure measurements
Number of subjects: 226
Study: 6444379

Group type: EXPERIMENTAL
Intervention: 20 percent benzoyl peroxide lotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31588886

Group type: COMPARATOR
Intervention: ZnSO4 (n = 15)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ZnAA (n = 14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CON (n = 15)
Number of subjects: 44
Study: 29388435

Group type: EXPERIMENTAL
Intervention: 4 home visits with a health educator, tailored emails, and mailed incentives (4HV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 home visits with a health educator, tailored emails, and mailed incentives (2HV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General health advice through emails (control)
Number of subjects: 45
Study: 28947449

Group type: EXPERIMENTAL
Intervention: Lifestyle Matters intervention (4-month occupational therapy intervention)
Number of subjects: 13
Study: 25824586

Group type: EXPERIMENTAL
Intervention: Valacyclovir (vACV) 8 g/day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Valganciclovir (vGCV) 900 mg/day
Number of subjects: 117
Study: 23429202

Group type: EXPERIMENTAL
Intervention: Avatar therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crossover control (TAU vs Avatar therapy)
Number of subjects: 0
Study: 22015094

Group type: EXPERIMENTAL
Intervention: 500 μM ASA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 26
Study: 18444110

Group type: EXPERIMENTAL
Intervention: Agreeableness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conscientiousness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personality facets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social information processing and behavioral discounting variables
Number of subjects: 0
Study: 17220051

Group type: EXPERIMENTAL
Intervention: Test formulation (rosiglitazone 8 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference formulation (rosiglitazone 8 mg)
Number of subjects: 28
Study: 12644428

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% and lidocaine 2%
Number of subjects: 90

Group type: COMPARATOR
Intervention: L-bupivacaine 0.75% and lidocaine 2%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 10335782

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus postoperative radiotherapy
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 1375
Study: 8529086

Group type: EXPERIMENTAL
Intervention: Behavioral and educational cardiac rehabilitation program, including 6 weekly group sessions and personalized behavior modification program.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 86
Study: 2153728

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7008293

Group type: EXPERIMENTAL
Intervention: Adjunctive antithymocyte globulin (ATG) therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard antirejection treatment (SAT)
Number of subjects: 90
Study: 31773201

Group type: EXPERIMENTAL
Intervention: ISB with DEX (1 ml DEX + 8 ml 0.75% ropivacaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ISB alone (1 ml normal saline + 8 ml ropivacaine)
Number of subjects: 50
Study: 31663769

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (o‐CEE; n = 109)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (t‐E2; n = 107)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo (n = 146)
Number of subjects: 362
Study: 30231542

Group type: EXPERIMENTAL
Intervention: White bread
Number of subjects: 7

Group type: COMPARATOR
Intervention: White rice
Number of subjects: 7
Study: 26600287

Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy for 10 weeks
Number of subjects: 212

Group type: COMPARATOR
Intervention: Topical overnight application of lidocaine for 10 weeks
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Topical overnight application of lidocaine
Number of subjects: 212
Study: 24470392

Group type: EXPERIMENTAL
Intervention: Black tea consumption
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 579
Study: 22172440

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 600

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 600
Study: 20855414

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention (n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care (n = 65)
Number of subjects: 130
Study: 17372057

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy
Number of subjects: 1536

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 1536
Study: 16295212

Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Melatonin 3.0 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11976562

Group type: EXPERIMENTAL
Intervention: 15 g young barley leaf extract (BL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 200 mg vitamin C and 200 mg vitamin E (CE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BL plus CE (BL + CE)
Number of subjects: 36
Study: 11276473

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Optimum medical management (risk factor reduction and initiation of antiplatelet therapy)
Number of subjects: 7
Study: 7831025

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 4
Study: 29405226

Group type: EXPERIMENTAL
Intervention: Solanezumab (400 mg) every 4 weeks for 80 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solanezumab (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28370397

Group type: EXPERIMENTAL
Intervention: Comprehensive education about dental implants delivered before the interview
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comprehensive education about dental implants delivered after completing the questionnaire
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Information about implants from relatives or own dentist
Number of subjects: 66

Group type: COMPARATOR
Intervention: Information about implants from the study dentist
Number of subjects: 66
Study: 26599866

Group type: EXPERIMENTAL
Intervention: n-butanol exposure (3.7 ppm)
Number of subjects: 36
Study: 22906391

Group type: EXPERIMENTAL
Intervention: Lip revision surgery
Number of subjects: 55
Study: 21250860

Group type: EXPERIMENTAL
Intervention: Alcaftadine 0.25% ophthalmic solution
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 58
Study: 19994698

Group type: EXPERIMENTAL
Intervention: Wooden needle treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Alprazolam (western medicine)
Number of subjects: 120
Study: 16762126

Group type: EXPERIMENTAL
Intervention: Spiritual healing (5 sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham healing (placebo delivered by an actor)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (normal care only)
Number of subjects: 88
Study: 14760591

Group type: EXPERIMENTAL
Intervention: Minimally invasive harvested veins
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventionally harvested grafts
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Minimally invasive harvested grafts
Number of subjects: 200
Study: 11318843

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) group
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group (non-diabetic women)
Number of subjects: 401
Study: 9228140

Group type: EXPERIMENTAL
Intervention: Mail-delivered arthritis self-management program
Number of subjects: 809

Group type: COMPARATOR
Intervention: Control group (no intervention for first 6 months)
Number of subjects: 809
Study: 7654434

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg/day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Ondansetron (24 mg/day)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg/day) in patients receiving cisplatin
Number of subjects: 309

Group type: COMPARATOR
Intervention: Ondansetron (24 mg/day) in patients receiving cisplatin
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg/day) in patients receiving ifosfamide
Number of subjects: 309

Group type: COMPARATOR
Intervention: Ondansetron (24 mg/day) in patients receiving ifosfamide
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 309

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 309
Study: 3673682

Group type: EXPERIMENTAL
Intervention: Internal neurolysis of the median nerve with a microsurgical technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Simple division of the carpal ligament (flexor retinaculum)
Number of subjects: 48
Study: 31039656

Group type: EXPERIMENTAL
Intervention: Metformin sterosomes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin-free solution aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin sterosomes and metformin-free solution aerosol
Number of subjects: 0
Study: 28578544

Group type: EXPERIMENTAL
Intervention: Workshop + Feedback
Number of subjects: 12

Group type: COMPARATOR
Intervention: Workshop Only
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both Intervention Groups
Number of subjects: 12
Study: 27465727

Group type: EXPERIMENTAL
Intervention: Enzyme-Treated Asparagus Extract (ETAS) 150 mg/d for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24108783

Group type: COMPARATOR
Intervention: 60,000 IU cholecalciferol
Number of subjects: 644

Group type: COMPARATOR
Intervention: 30,000 IU cholecalciferol
Number of subjects: 644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644

Group type: COMPARATOR
Intervention: 60,000 IU cholecalciferol in subjects aged ≥70 y
Number of subjects: 644

Group type: COMPARATOR
Intervention: 60,000 IU cholecalciferol in subjects aged <70 y
Number of subjects: 644